Botulinum neurotoxins and botulism: A novel therapeutic approach

Toxins

Volumn 3, Issue 5, 2011, Pages 469-488

  Thanongsaksrikul, Jeeraphong ^a   Chaicumpa, Wanpen ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Botulinum neurotoxin; Botulism; Cell penetrating peptide (CPP); Chimeric antibody; Heavy chain antibody (HCAb); Humanized antibody; Humanized camel phage display library; Immunotherapy; Nanobody; Phage display; Serum therapy; Single chain antibody variable fragment (ScFV); Single domain antibody (sdAb); Therapeutic antibody; Transbody; VHH; VH; VL; Zinc metalloprotease

Indexed keywords

BIVALENT EQUINE ANTITOXIN; BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN D; BOTULINUM TOXIN E; BOTULINUM TOXIN F; BOTULINUM TOXIN G; CELL PENETRATING PEPTIDE; FULLY HUMAN MONOCLONAL ANTIBODY; HEPTAVALENT EQUINE ANTITOXIN; HUMAN BOTULISM IMMUNE GLOBULIN; HUMAN MOUSE CHIMERIC ANTIBODY; HYBRID PROTEIN; METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOVALENT EQUINE ANTITOXIN; MOUSE MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT ANTITOXIN; SINGLE DOMAIN ANTIBODY; TRIVALENT EQUINE ANTITOXIN; UNCLASSIFIED DRUG;

BOTULISM; CELL MEMBRANE; CHEMICAL STRUCTURE; CLINICAL FEATURE; CYTOPLASM; DRUG BINDING; ENZYME ACTIVITY; HUMAN; IMMUNOTHERAPY; MOLECULAR DOCKING; MOLECULAR SIZE; NONHUMAN; PHAGE DISPLAY; PHARMACOLOGICAL BLOCKING; RECEPTOR BINDING; REVIEW; SEQUENCE HOMOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; BOTULISM; HUMANS; NEUROTOXINS; SINGLE-DOMAIN ANTIBODIES;

ANIMALIA;

EID: 79958033240     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins3050469     Document Type: Review

References (127)

1. Sugiyama, H. Clostridium botulinum neurotoxin. Microbiol. Rev. 1980, 44, 419-448.
2. Gill, D.M. Bacterial toxins: A table of lethal amounts. Microbiol. Rev. 1982, 46, 86-94.
3. Hatheway, C.L. Toxigenic clostridia. Clin. Microbiol. Rev. 1990, 3, 66-98.
4. Rotz, L.D.; Khan, A.S.; Lillibridge, S.R.; Ostroff, S.M.; Huhge, J.M. Public health assessment of potential biological terrorism agents. Emerg. Infect. Dis. 2002, 8, 225-230.
5. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M.T.; O'Toole, T.; Parker, G.; Perl, T.M.; Russell, P.K.; Swerdlow, D.L.; Tonat, K. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001, 285, 1059-1070.
6. Fuginaga, Y.; Matsumura, T.; Jin, Y.; Takegahara, Y.; Sugawara, Y. A novel function of botulinum toxin-associated proteins: HA proteins disrupt intestinal epithelial barrier to increase toxin absorption. Toxicon 2009, 54, 583-586.
7. Poulain, B.; Popoff, M.R.; Molgo, J. How to botulinum neurotoxins block neurotransmitter release: From botulism to the molecular mechanism of action. The Botulinum J. 2008, 1, 14-56.
8. Whelan, S.M.; Elmore, M.J.; Bodsworth, N.J.; Brehm, J.K.; Atkinson, T.; Minton, N.P. Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl. Environ. Microbiol. 1992, 58, 2345-2354.
9. Sebaihia, M.; Peck, M.W.; Minton, N.P.; Thomson, N.R.; Holden, M.T.G.; Mitchell, W.J.; Carter, A.T.; Bentley, S.D.; Mason, D.R.; Crossman, L.; et al. Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes. Genome Res. 2007, 17, 1082-1092.
10. Inoue, K.; Iida, H. Conversion of toxigenicity in Clostridium botulinum type C. Jpn. J. Microbiol. 1970, 14, 87-89.
11. Eklund, M.W.; Poysky, F.T.; Reed, S.M. Bacteriophage and the toxigenicity of Clostridium botulinum type D. Nat. New Biol. 1972, 235, 16-17.
12. Eklund, M.W.; Poysky, F.T.; Mseitif, L.M.; Strom, M.S. Evidence for plasmid-mediated toxin and bacteriocin production in Clostridium botulinum type G. Appl. Environ. Microbiol. 1988, 54, 1405-1408.
13. Franciosa, G.; Maugliani, A.; Scalfaro, C.; Aureli, P. Evidence that plasmid-borne botulinum neurotoxin type B genes are widespread among Clostridium botulinum serotype B strains. PLoS ONE 2009, 4, e4829.
14. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898-902.
15. Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7, 693-699.
16. Schiavo, G.; Rossetto, O.; Santucci, A.; DasGupta, B.R.; Montecucco, C. Botulinum neurotoxins are zinc protein. J. Biol. Chem. 1992, 267, 23479-23483.
17. Brunger, A.T.; Rummel, A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009, 54, 550-560.
18. Thanongsaksrikul, J. Therapeutic Antibodies for Disease Caused by Biological Weapon(s). Ph.D. Thesis, Mahidol University, Thailand, 2010.
19. Maksymowych, A.B.; Simpson, L.L. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem. 1998, 273, 21950-21957.
20. Rummel, A.; Eichner, T.; Weil, T.; Karnath, T.; Gutcaits, A.; Mahrhold, S.; Sandhoff, K.; Proia, R.L.; Acharya, K.R.; Bigalke, H.; Binz, T. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. USA 2007, 104, 359-364.
21. Dong, M.; Tepp, W.H.; Liu, H.; Johnson, E.A.; Chapman, E.R. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell. Biol. 2007, 179, 1511-1522.
22. Dong, M.; Yeh, F.; Tepp, W.H.; Dean, C.; Johnson, E.A.; Janz, R.; Chapman, E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312, 592-596.
23. Schmidt, M.F.; Robinson, J.P.; DasGupta, B.R. Direct visualization of botulinum neurotoxin-induced channels in phospholipid vesicles. Nature 1993, 364, 827-830.
24. Koriazova, L.K.; Montal, M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 2003, 10, 13-18.
25. Brunger. A.T.; Jin, R.; Breidenbach, M.A. Highly specific interaction between botulinum neurotoxins and synaptic vesicle proteins. Cell. Mol. Life Sci. 2008, 65, 2296-2306.
26. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717-766.
27. Blasi, J.; Chapman, E.R.; Link, E.; Binz, T.; Yamasaki, S.; de Camilli, P.; Südhof, T.C.; Niemann, H.; Jahn, R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365, 160-163.
28. Schiavo, G.; Rossetto, O.; Catsicas, S.; Polverino de Laureto, P.; DasGupta, B.R.; Benfenati, F.; Montecucco, C. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 1993, 268, 23784-23787.
29. Binz, T.; Blasi, J.; Yamasaki, S.; Baumeister, A.; Link, E.; Südhof, T.C.; Jahn, R.; Niemann, H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol. Chem. 1994, 269, 1617-1620.
30. Schiavo, G.; Shone, C.C.; Bennett, M.K.; Scheller, R.H.; Montecucco, C. Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J. Biol. Chem. 1995, 270, 10566-10570.
31. Blasi, J.; Chapman, E.R.; Yamasaki, S.; Binz, T.; Niemann, H.; Jahn, R. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J. 1993, 12, 4821-4828.
32. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; de Laureto, P.P.; DasGupta, B.R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359, 832-835.
33. Schiavo, G.; Shone, C.C.; Rossetto, O.; Alexander, F.C.; Montecucco, C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J. Biol. Chem. 1993, 268, 11516-11519.
34. Yamasaki, S.; Baumeister, A.; Binz, T.; Blasi, J.; Link, E.; Cornille, F.; Roques, B.; Fykse, E.M.; Südhof, T.; Jahn, R.; Niemann, H. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 1994, 269, 12764-12772.
35. Yamasaki, S.; Binz, T.; Hayashi, T.; Szabo, E.; Yamasaki, N.; Eklund, M.; Jahn, R.; Niemann, H. Botulinum neurotoxin type G proteolyzes the Ala81-Ala82 bond of Rat synaptobrevin 2. Biochem. Biophys. Res. 1994, 200, 829-835.
36. Emmeluth, D. Botulism (Deadly Disease and Epidemics), 1st ed.; Chelsea House Publishers: Broomall, PA, USA, 2005.
37. Cenci di Bello, I.; Poulain, B.; Shone, C.C.; Tauc, L.; Dolly, J.O. Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes. Eur. J. Biochem. 1994, 219, 161-169.
38. Anne, C.; Turcaud, S.; Quancard, J.; Teffo, F.; Meudal, H.; Fournié-Zaluski, M.C.; Roques, B.P. Development of potent inhibitors of botulinum neurotoxin type B. J. Med. Chem. 2003, 46, 4648-4656.
39. Blommaert, A.; Turcaud, S.; Anne, C.; Roques, B.P. Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of botulinum neurotoxin B metallo-proteolytic activity. Bioorg. Med. Chem. 2004, 12, 3055-3062.
40. Koenig, M.G. Trivalent botulinus antotoxin. Ann. Intern. Med. 1969, 70, 643-645.
41. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR 2010, 59, 299.
42. U.S. Food and Drug. Alphabetical List of Licensed Products: Information Updated through February 28, 2011. Available online: http://www.fda.gov/downloads/BiologicsBloodVaccines/ UCM149970.pdf (accessed on 27 March 2011).
43. Arnon, S.S.; Schechter, R.; Maslanka, S.E.; Jewell, N.P.; Hatheway, C.L. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 2006, 354, 462-471.
44. Arnon, S.S. Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics 2007, 119, 785-789.
45. Nowakowski, A.; Wang, C.; Powers, D.B.; Amersdorfer, P.; Smith, T.J.; Montgomery, V.A.; Sheridan, R.; Blake, R.; Smith, L.A.; Marks, J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 2002, 99, 11346-11350.
46. Levy, R.; Forsyth, C.M.; LaPorte, S.L.; Geren, I.N.; Smith, L.A.; Marks, J.D. Fine and Domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J. Mol. Biol. 2007, 365, 196-210.
47. Lou, J.; Geren, I.; Garcia-Rodriguez, C.; Forsyth, C.M.; Wen, W.; Knopp, K.; Brown, J.; Smith, T.; Smith, L.A.; Marks, J.D. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng. Des. Sel. 2010, 23, 311-319.
48. Atassi, M.Z. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action. Toxicon 2009, 54, 600-613.
49. Cheng, L.W.; Stanker, L.H.; Henderson, T.D., II; Lou, J.; Marks, J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 2009, 77, 4305-4313.
50. Keller, M.A.; Stiehm, E.R. Passive immunity in prevention of infectious diseases. Clin. Microbiol. Rev. 2000, 13, 602-614.
51. Ellis, M.; Chir, B. Human antitetanus serum in the treatment of tetanus. Br. Med. J. 1963, 1, 1123-1126.
52. Gallagher, J.R. Use of convalescent measles serum to control measles in a preparatory school. Am. J. Public Health Nations Health 1935, 25, 595-598.
53. Casadevall, A.; Pirofski, L.A. New concepts in antibody-mediated immunity. Infect. Immun. 2004, 72, 6191-6196.
54. Orange, J.S.; Hossny, E.M.; Weiler, C.R.; Ballow, M.; Berger, M.; Bonilla, F.A.; Buckley, R.; Chinen, J.; El-Gamal, Y.; Mazer, B.D.; Nelson, R.P., Jr.; Patel, D.D.; Secord, E.; Sorensen, R.U.; Wasserman, R.L.; Cunningham-Rundles, C. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology. J. Allerg. Clin. Immunol. 2006, 117, 525-553.
55. Deng, Y-Q.; Dai, J-X.; Ji, G-H.; Jiang, T.; Wang, H-J.; Yang, H.; Tan, W-L.; Liu, R.; Yu, M.; Ge, B-X.; Zhu, Q-Y.; Qin, E-D.; Guo, Y-J.; Qin, C-F. A broadly Flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within fushion loop of E protein. PLoS ONE 2011, 6, e16059.
56. Blanchard, T.G.; Czinn, S.J.; Maurer, R.; Thomas, W.; Soman, G.; Nedrud, J.G. Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect. Immun. 1995, 63, 1394-1399.
57. Colomar, M.; Puga, I.; López, M.; Massot, M.; Jorquera, J.I.; Reina, M.; Vilaró, S.; Espel, E. Neutralization of measles virus infectivity and antibody-dependent cell-mediated cytotoxicity activity against an Epstein-Barr virus-infected cell line by intravenous administration of immunoglobulin G. Clin. Diagn. Lab. Immunol. 2003, 10, 751-756.
58. Han, Y.; Kozel, T.R.; Zhang, M.X.; MacGill, R.S.; Carroll, M.C.; Cutler, J.E. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental hematogenously disseminated candidiasis. J. Immunol. 2001, 167, 1550-1557.
59. Köhler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
60. Haurum, J.S. Recombinant polyclonal antibodies: The next generation of antibody therapeutics? Drug Discov. Today 2006, 11, 655-660.
61. Casadevall, A.; Scharff, M.D. Return to the past: The case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 1995, 21, 150-161.
62. Nelson, A.L.; Reichert, J.M. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 2009, 27, 331-337.
63. Li, J.; Zhu, Z. Research and development of next generation of antibody-based therapeutics. Acta. Pharmacol. Sin. 2010, 31, 1198-1207.
64. Mazuet, C.; Dano, J.; Popoff, M.R.; Créminon, C.; Volland, H. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS ONE 2010, 5, e12416.
65. Köhler, G. Immunoglobulin chain loss in hybridoma lines. Proc. Natl. Acad. Sci. USA 1980, 77, 2197-2199.
66. Courtenay-Luck, N.S.; Epenetos, A.A.; Winearls, C.G.; Ritter, M.A. Preexisting human anti-murine immunoglobulin reactivity due to polyclonal rheumatoid factors. Cancer Res. 1987, 47, 4520-4525.
67. Tjandra, J.J.; Ramadi, L.; McKenzie, I.F.C. Development of human anti-murine antibody (HAMA) response in patients. Immunol. Cell Biol. 1990, 68, 367-376.
68. Losman, M.J.; DeJager, R.L.; Monostier, M.; Sharkey, R.M.; Goldenberg, D.M. Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies. Cancer Res. 1990, 1, 1055-1058.
69. Morrison, S.L.; Johnson, M.J.; Herzenberg, L.A.; Oi, V.T. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 1984, 81, 6851-6855.
70. Stern, M.; Herrmann, R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit. Rev. Oncol. Hematol. 2005, 54, 11-29.
71. Normann, S.J. Why antibody inhibits vascular clearance of staphylococcal enterotoxin B. J. Immunol. 1970, 104, 673-678.
72. Devaux C.; Moreau, E.; Goyffon, M.; Rochat, H.; Billiald, P. Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur. J. Biochem. 2001, 268, 694-702.
73. Christensen, E.I.; Verrous, P.J.; Nielsen, R. Receptor-mediated endocytosis in renal proximal tubule. Pflug. Arch. Eur. J. Phys. 2009, 458, 1039-1048.
74. Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. Reshaping human antibodies for therapy. Nature 1988, 332, 323-327.
75. Maneewatch, S.; Sakolvaree, Y.; Tapchaisri, P.; Saengjaruk, P.; Songserm, T.; Wongratanachewin, S.; Tongtawe, P.; Srimanote, P.; Chaisri, U.; Chaicumpa, W. Humanized-monoclonal antibody against heterologous Leptospira infection. Protein Eng. Des. Sel. 2009, 22, 305-312.
76. Reichert, J.; Pavlou, A. Monoclonal antibodies market. Nat. Rev. Drug Discov. 2004, 3, 383-384.
77. Brüggemannand, M.; Taussig, M.J. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol. 1997, 8, 455-458.
78. Chiorazzi, N.; Wasserman, R.L.; Kunkel, H.G. Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas. J. Exp. Med. 1982, 156, 930-935.
79. Rosen, A.; Persson, K.; Klein, G. Human monoclonal antibodies to a genus-specific chlamydial antigen produced by EBV-transformed B cells. J. Immunol. 1983, 130, 2899-2902.
80. Garzelli, C.; Puglisi, C.; Falcone, G. Human monoclonal antibody to purified protein derivative of tuberculin produced by hybrids constructed with Epstein-Barr virus-transformed B lymphocytes and mouse myeloma cells. Eur. J. Immunol. 1986, 16, 584-587.
81. Foung, S.K.H.; Perkins, S.; Raubitschek, A.; Larrick, J.; Lizak, G.; Fishwild, D.; Engleman, E.G.; Grumet, F.C. Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J. Immunol. Methods 1984, 70, 83-90.
82. Goldsby, R.A.; Kindt, T.J.; Osborne, B.A. Kuby Immunology, 5th ed.; W.H. Freeman and Company: New York, NY, USA, 2003; Chapter 5, pp. 105-136.
83. Maizels, N. Immunoglobulin gene diversification. Annu. Rev. Genet. 2005, 39, 23-46.
84. Boder, E.T.; Wittrup, K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 1997, 15, 553-557.
85. Daugherty, P.S.; Olsen, M.J.; Iverson, B.L.; Georgiou, G. Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng. 1999, 12, 613-621.
86. Beerli, R.R.; Bauer, M.; Buser, R.B.; Gwerder, M.; Muntwiler, S.; Maurer, P.; Saudan, P.; Bachmann, M.F. Isolation of human monoclonal antibodies by mammalian cell display. Proc. Natl. Acad. Sci. USA 2008, 105, 14336-14341.
87. Hanes, J.; Plückthun, A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA 1997, 94, 4937-4942.
88. Smith, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228, 1315-1317.
89. Hoogenboom, H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 2005, 23, 1105-1116.
90. Kulkeaw, K.; Sakolvaree, Y.; Srimanote, P.; Tongtawe, P.; Maneewatch, S.; Sookrung, N.; Tungtrongchitr, A.; Tapchaisri, P.; Kurazono, H.; Chaicumpa, W. Human monoclonal ScFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin. J. Proteomics 2009, 72, 270-282.
91. Hoogenboom, H.R. Overview of antibody phage-display technology and its applications. In Antibody Phage Display: Methods and Protocols; O'Brien, P.M., Aitken, R., Eds.; Humana Press Inc.: Totowa, NJ, USA, 2002; pp. 1-37.
92. Sidhu, S.S.; Fellouse, F.A. Synthetic therapeutic antibodies. Nat. Chem. Biol. 2006, 2, 682-688.
93. Winter, G.; Griffiths, A.D.; Hawkins, R.E.; Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 1994, 12, 433-455.
94. de Haard, H.J.; Kazemier, B.; van der Bent, A.; Oudshoorn, P.; Boender, P.; van Gemen, B.; Arends, J.W.; Hoogenboom, H.R. Absolute conservation of residue 6 of immunoglobulin heavy chain regions of class IIA is required for correct folding. Protein Eng. 1998, 11, 1267-1276.
95. Maneewatch, S.; Thanongsaksrikul, J.; Songserm, T.; Theung-In, K.; Kulkeaw, K.; Thathisong, U.; Srimanote, P.; Tongtawe, P.; Tapchaisri P.; Chaicumpa, W. Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1. Antivir. Ther. 2009, 14, 221-230.
96. Poungpair, O.; Chaicumpa, W.; Kulkeaw, K.; Maneewatch, S.; Theung-In, K.; Srimanote, P.; Tongtawe, P.; Songserm, T.; Lekcharoensuk, P.; Tapchaisri, P. Human single chain monoclonal antibody that recognizes matrix protein of heterologous influenza A virus subtype. J. Virol. Methods 2009, 159, 105-111.
97. HH that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J. Biol. Chem. 2010, 285, 9657-9666.
98. Joosten, V.; Lokman, C.; van den Hondel, C.A.; Punt, P.J. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb. Cell. Fact. 2003, 2, 1-15.
99. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E.B.; Bendahman, N.; Hamers, R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363, 446-448.
100. Davies, J.; Riechmann, L. Camelising human antibody fragments: NMR studies on VH domains. FEBS Lett. 1994, 339, 285-290.
101. Muyldermans, S.; Atarhouch, T.; Saldanha, J.; Barbosa, J.A.; Hamers, R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994, 7, 1129-1135.
102. Nguyen, V.K.; Hamers, R.; Muyldermans, S. Camel heavy-chain antibodies: Diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000, 19, 921-930.
103. Conrath, K.E.; Wernery, U.; Muyldermans, S.; Nguyen, V.K. Emergence and evolution of functional heavy-chain antibodies in Camelidae. Dev. Comp. Immunol. 2003, 27, 87-103.
104. Wu, T.T.; Johnson, G.; Kabat, E.A. Length distribution of CDRH3 in antibodies. Proteins 1993, 16, 1-7.
105. Muyldermans, S. Single domain camel antibodies: Current status. J. Biotechnol. 2001, 74, 277-302.
106. Desmyter, A.; Decanniere, K.; Muyldermans, S.; Wyns, L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. 2001, 276, 26285-26290.
107. de Genst, E.; Silence, K.; Decannierer, K.; Conrath, K.; Loris, R.; Kinne, J.; Muyldermans, S.; Wyns, L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. USA 2006, 103, 4586-4591.
108. Lauwereys, M.; Ghahroudi, M.A.; Desmyter, A.; Kinne, J.; Holzer, W.; de Genst, E.; Wyn, L.; Muyldermans, S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998, 17, 3512-3520.
109. Conrath, K.E.; Lauwereys, M.; Galleni, M.; Matagne, A.; Frere, J.M.; Kinne, J.; Wyn, L.; Muyldermans, S. β-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob. Agents Chemother. 2001, 45, 2807-2812.
110. Ghahroudi, M.A.; Desmyter, A.; Wyns, L.; Hamers, R.; Muyldermans, S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997, 414, 521-526.
111. Harmsen, M.M.; de Haard, H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77, 13-22.
112. Chulanetra, M.; Chaicumpa, W. Human antibody that neutralizes tetrodotoxin. Mahidol University, Thailand. Unpublished work, 2011.
113. Muyldermans, S.; Cambillau, C.; Wyns, L. Recognition of antigens by single domain antibody fragments: The superfluous luxury of paired domains. TIBS 2001, 26, 230-235.
114. Dong, J.; Thompson, A.A.; Fan, Y.; Lou, J.; Conrad, F.; Ho, M.; Pires-Alves, M.; Wilson, B.A.; Stevens, R.C.; Marks, J.D. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic α-exosite binding region. J. Mol. Biol. 2010, 397, 1106-1118.
115. Conway, J.O.; Sherwood, L.J.; Collazo, M.T.; Garza, J.A.; Hayhurst, A. Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS ONE 2010, 5, e8818.
116. Derossi, D.; Joliot, A.H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 269, 10444-10450.
117. Pooga, M.; Hallbrink, M.; Zorko, M.; Langel, U. Cell penetration by transpotan. FASEB J. 1998, 12, 67-77.
118. Poungpair, O.; Pootong, A.; Maneewatch, S.; Srimanote, P.; Tongtawe, P.; Songserm, T.; Tapchaisri, P.; Chaicumpa,W. A human single chain transbody specific to matrix protein (M1) interferes with the replication of Influenza A virus. Bioconjugate Chem. 2010, 21, 1134-1141.
119. Noguchi, H.; Matsumoto, S. Protein transduction technology: A novel therapeutic perspective. Acta Med. Okayama 2006, 60, 1-11.
120. Lundberg, M.; Johansson, M. Is VP22 nuclear homing an artifact? Nat. Biotechnol. 2001, 19, 713-714.
121. Letoha, T.; Gaal, S.; Somlai, C.; Czajlik, A.; Perczel, A.; Penke, B. Membrane translocation of penetratin and its derivatives in different cell lines. J. Mol. Recognit. 2003, 16, 272-279.
122. Saalik, P.; Elmquist, A.; Hansen, M.; Padari, K.; Saar, K.; Viht, K.; Langel, U.; Pooga, M. Protein cargo delivery properties of cell-penetrating peptides: A comparative study. Bioconjugate Chem. 2004, 15, 1246-1253.
123. Kaplan, I.M.; Wadia, J.S.; Dowdy, S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Release 2005, 102, 247-253.
124. Richard, J.P.; Melikov, K.; Brooks, H.; Prevot, P.; Lebleu, B.; Chernomordik, L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparin sulfate receptors. J. Biol. Chem. 2005, 280, 15300-15306.
125. Morris, M.C.; Deshayes, S.; Heitz, F.; Divita, G. Cell-penetrating peptides: From molecular mechanisms to therapeutics. Biol. Cell 2008, 100, 201-217.
126. Raha, S.; Paunesku, T.; Woloschak, G. Peptide-mediated cancer targeting of nanoconjugates. WIREs Nanomed. Nanobiotechnol. 2010, 3, 269-281.
127. Deshayes, S.; Morris, M.C.; Divita, G.; Heitz, F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell Mol. Life Sci. 2005, 62, 1839-1849.